MLi-2 is a highly selective inhibitor of orally active LRRK2. MLi-2 is highly active, with an IC50 value of 0.76 nM in vitro assay of purified LRRK2 kinase, 1.4 nM in cell assay monitoring LRRK2 pSer935 LRRK2 dephosphorylation, and 3.4 nM in radioland competitive binding assay.

 

Brand: BCM

 

Target: LRRK2

 

Signaling Pathways: Autophagy

 

Boiling Point: 625.8±55.0 °C(Predicted)

 

pKa: 11.24±0.40(Predicted)

 

Solubility: Soluble in DMSO. Insoluble in Water; insoluble in Ethanol.

 

Isomeric SMILES: C[C@@H]1CN(C[C@@H](O1)C)C2=NC=NC(=C2)C3=NNC4=C3C=C(C=C4)OC5(CC5)C  

 

InChIKey: ATUUNJCZCOMUKD-OKILXGFUSA-N  

 

InChI: InChI=1S/C21H25N5O2/c1-13-10-26(11-14(2)27-13)19-9-18(22-12-23-19)20-16-8-15(28-21(3)6-7-21)4-5-17(16)24-25-20/h4-5,8-9,12-14H,6-7,10-11H2,1-3H3,(H,24,25)/t13-,14+

 

Attribute
[Chem Name]	(2R,6S)-2,6-dimethyl-4-[6-[5-(1-methylcyclopropyl)oxy-1H-indazol-3-yl]pyrimidin-4-yl]morpholine
[Synonym]	MLi-2
[CAS No.]	1627091-47-7
[MDL No.]	MFCD30536362
[Formula]	C21H25N5O2
[Molecular]	379.46
[Form]	A crystalline solid
[Storage]	Sealed in dry. Store in freezer, under -20°C

Goods Tag